Oba Mitsunobu, Nakanishi Yoshitsugu, Mitsuhashi Tomoko, Sasaki Katsunori, Hatanaka Kanako C, Sasaki Masako, Nange Ayae, Okumura Asami, Hayashi Mariko, Yoshida Yusuke, Nitta Takeo, Ueno Takashi, Yamada Toru, Ono Masato, Kuwabara Shota, Okamura Keisuke, Tsuchikawa Takahiro, Nakamura Toru, Noji Takehiro, Asano Toshimichi, Tanaka Kimitaka, Takayama Kiyoshi, Hatanaka Yutaka, Hirano Satoshi
Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo 060-8638, Japan.
Department of Surgical Pathology, Hokkaido University Hospital, Sapporo 060-8648, Japan.
Cancers (Basel). 2023 Mar 21;15(6):1878. doi: 10.3390/cancers15061878.
The epithelial-mesenchymal transition (EMT) contributes to the metastatic cascade in various tumors. C-C chemokine receptor 7 (CCR7) interacts with its ligand, chemokine (C-C motif) ligand 19 (CCL19), to promote EMT. However, the association between EMT and CCR7 in extrahepatic cholangiocarcinoma (EHCC) remains unknown. This study aimed to elucidate the prognostic impact of CCR7 expression and its association with clinicopathological features and EMT in EHCC. The association between CCR7 expression and clinicopathological features and EMT status was examined via the immunohistochemical staining of tumor sections from 181 patients with perihilar cholangiocarcinoma. This association was then investigated in TFK-1 and EGI-1 EHCC cell lines. High-grade CCR7 expression was significantly associated with a large number of tumor buds, low E-cadherin expression, and poor overall survival. TFK-1 showed CCR7 expression, and Western blotting revealed E-cadherin downregulation and vimentin upregulation in response to CCL19 treatment. The wound healing and Transwell invasion assays revealed that the activation of CCR7 by CCL19 enhanced the migration and invasion of TFK-1 cells, which were abrogated by a CCR7 antagonist. These results suggest that a high CCR7 expression is associated with an adverse postoperative prognosis via EMT induction and that CCR7 may be a potential target for adjuvant therapy in EHCC.
上皮-间质转化(EMT)在多种肿瘤的转移过程中发挥作用。C-C趋化因子受体7(CCR7)与其配体趋化因子(C-C基序)配体19(CCL19)相互作用,促进EMT。然而,肝外胆管癌(EHCC)中EMT与CCR7之间的关联尚不清楚。本研究旨在阐明CCR7表达对EHCC的预后影响及其与临床病理特征和EMT的关系。通过对181例肝门部胆管癌患者肿瘤切片进行免疫组织化学染色,检测CCR7表达与临床病理特征及EMT状态之间的关联。随后在TFK-1和EGI-1 EHCC细胞系中研究这种关联。CCR7高表达与大量肿瘤芽、低E-钙黏蛋白表达及总体生存率差显著相关。TFK-1显示CCR7表达,蛋白质印迹法显示CCL19处理后E-钙黏蛋白下调和波形蛋白上调。伤口愈合和Transwell侵袭试验表明,CCL19激活CCR7可增强TFK-1细胞的迁移和侵袭,而CCR7拮抗剂可消除这种作用。这些结果表明,CCR7高表达通过诱导EMT与术后不良预后相关,且CCR7可能是EHCC辅助治疗的潜在靶点。